Clinical Trials Logo

Clinical Trial Summary

The study will investigate if treatment with Roxadustat improves kidney oxygenation in diabetic patients with nephropathy receiving treatment for renal anemia, compared to patients receiving treatment with darbepoetin alpha. Participants will be randomized to either treatment, and receive equal care for renal anemia. Kidney oxygenation will be examined before treatment start and after 24 weeks using BOLD-MRI (blood oxygen level-defendant MRI), a non-invasive method available for measurement of tissue oxygenation levels that is comparable with direct invasive measurement of partial oxygen pressure. Blood and urin samples will be collected in connection to these visits. The primary endpoint is the change in medullary and cortical R2* (inversely proportional to the tissue oxygenation content) after 24 weeks. Secondary endpoints will be albuminuria and urinary levels of ROS (evaluated by electron paramagnetic resonance (EPR) spectroscopy with CPH spin probes).


Clinical Trial Description

Aims The general aim of this study is to investigate the effects of systemic administration of Evrenzo (Roxadustat [RD]) or Aranesp (darbepoetin alpha [DA]) on the levels of renal oxygenation in patients with diabetic nephropathy and associated anemia. The investigation will elucidate if RD, a prolyl-hydroxylase (PHD) inhibitor and subsequent Hypoxia-Inducible Factor 1 (HIF) activator, can reduce renal hypoxia, compared to DA, which lacks effects on HIF. Background Diabetes complications represent a huge health problem and concern for modern diabetes therapy, with dramatic consequences for the affected individuals and society. Diabetic kidney disease (DKD) is the most common cause of end-stage renal disease (ESRD) and accounts for a high morbidity and mortality rate in patients with diabetes. Today, the treatment for DKD focuses on optimizing the patients' metabolic control, blood lipid levels and blood pressure, which unfortunately is optimally achieved in just a restricted portion of patients (1). Thus, there is a great need of identifying novel therapies that could improve or prevent progression DKD. While hyperglycemia is the major factor contributing to the development of diabetes complications, the role of hypoxia has recently become increasingly evident as another central factor in all diabetes complications (2). Several effects may contribute to the development of hypoxia in diabetes, including deficient blood supply secondary to micro- and macro-vascular disease, poor local oxygen diffusion secondary to local oedema, or as a result of increased oxygen consumption (3, 4, 5, 6). HIF-1, a heterodimeric transcription factor, is a central regulator of cellular adaptive response to hypoxia (7). HIF consists of two subunits (alpha and beta), both constitutively expressed in mammalian cells. In normoxia, HIF-1alpha is continuously degraded by the ubiquitin-proteasome system because of the oxygen-dependent hydroxylation of two key proline residues catalyzed by a group of enzymes known as prolyl-hydroxylases (PHDs) (7). Upon hypoxia, this degradation pathway is suppressed and HIF-1alpha is stabilized, translocates to the nucleus where it dimerizes with HIF-1beta and induces the expression of more than 800 genes involved in angiogenesis, glycolytic energy metabolism, proliferation and survival that enables the cells to adapt to reduced oxygen availability (8, 9). HIF-1 is central for expression of several angiogenic growth factors (e.g., VEGF, erythropoietin (EPO), stromal cell-derived factor-1alpha) (10). Lately, accumulating evidence points to a defective cellular response to hypoxia in diabetes. This defective hypoxia response has been shown to be present in all tissues that develop complications in both animal models for diabetes and in patients with diabetes as a consequence of impaired HIF signaling, and there is a direct suppressive effect of hyperglycemia on HIF function (11). Studies in animal models of diabetes have demonstrated that restoring HIF function in hyperglycemia can prevent the development of multiple diabetes complications, including DKD (7). RD is a PHD inhibitor that stabilizes HIF-1 by preventing PHD dependent degradation of HIF-1alpha, and has recently been approved for treatment of renal anemia. As hypoxia plays a central pathogenic role even in the early stages of DKD (12), and activation of HIF signaling has recently been demonstrated to have protective effects in animal models of DKD (13), it is of great interest to also investigate the potential role of RD as a targeted therapy for DKD in humans. The presently proposed project aims to investigate the potential of RD to improve renal oxygenation in patients with DKD and anemia, compared to DA which lacks the above-mentioned effects on HIF and is an alternative treatment for the same condition. To examine this the investigators plan to use BOLD-MRI (blood oxygen level-defendant MRI), a non-invasive method available for measurement of tissue oxygenation levels that is comparable with direct invasive measurement of partial oxygen pressure (14). Research design The research design is a randomized prospective, open-label study with parallel groups of 15 participants/group with non-dialysis dependent DKD CKD stage 3-4 with Hb <10g/dl (the level of Hb recommended for RD/DA treatment). One group will receive Roxadustat (Evrenzo) three times weekly at an initial dose of 70mg (for body weight <100.0 kg) or 100 mg (for body weight weight ≥100.0 kg). The control group will receive darbepoietin alpha (Aranesp) s.c. 0.45mg/kg once a week. The dosage for both arms will be adjusted to keep Hb at the recommended levels between 11-12g/dl. Kidney oxygenation will be evaluated using BOLD-MRI prior to start of therapy, and once again after 24 weeks of treatment with either RD or DA. Primary endpoint is the change in medullary and cortical R2* (inversely proportional to the tissue oxygenation content) after 24 weeks. Secondary endpoints will be albuminuria and urinary levels of ROS (evaluated by electron paramagnetic resonance (EPR) spectroscopy with CPH spin probes). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05810311
Study type Interventional
Source Region Stockholm
Contact Sergiu Catrina, Ass. prof.
Phone +46-8-51775449
Email sergiu.catrina@ki.se
Status Not yet recruiting
Phase Phase 2
Start date January 1, 2024
Completion date December 31, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT03022721 - Heidelberg Study on Diabetes and Complications N/A
Withdrawn NCT02580266 - Blood/Urine Markers for Drug Discovery for Renal Disease in Diabetes
Completed NCT02423434 - Evaluation of Corneal Confocal Microscopy for the Identification and Prediction of Neuropathy in Type 1 Diabetes
Completed NCT01695278 - A Pilot Intervention Study of Health Coaching to Promote Diabetes Self-Care in the Community Phase 3
Completed NCT03426566 - Abnormal Plantar Pressure in Patients With Diabetes
Completed NCT02588898 - B-Vitamins and Polyneuropathy in Patients With Type 2 Diabetes
Completed NCT00815178 - Effects of Inspiratory Muscle Training on Type 2 Diabetes Mellitus Patients With Inspiratory Muscle Weakness N/A
Not yet recruiting NCT04537676 - Patient Empowerment Study
Terminated NCT02915263 - The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes Phase 2
Completed NCT01929018 - Collaborative-care Rehabilitation After Dysvascular Amputation N/A
Completed NCT03877523 - Cocarnit Effects on Macrophages Polarization N/A
Completed NCT02928939 - Therapeutic Conflicts and Multimorbidity
Completed NCT02947828 - Polyneuropathy in Diabetes Mellitus Type 2
Recruiting NCT02275091 - Children With Diabetes at Risk for Heart Disease.
Terminated NCT00529204 - Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease Phase 2
Not yet recruiting NCT05074849 - Benefits of Insoles With Real-Time Alert and Foot Self-Care Education N/A
Completed NCT04963998 - Safety and Efficacy Study of MedCu Wound Dressings N/A
Recruiting NCT06321029 - Electronic Diabetes Tune-Up Group (eDTU) for African Americans N/A
Active, not recruiting NCT03620773 - Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes Phase 1/Phase 2
Completed NCT05231642 - Individualised Postprandial Glucose Responses in Type 1 Diabetes N/A